In CML LSCs from chronic phase patients, EZH1 expression levels were low relative to normal HSCs, while EZH2 and a number of co-factors including Suz12, Jarid2, and PHF19 were all upregulated (Scott et al., 2016). The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.